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Background and Aims: Familial hypercholesterolemia (FH) is one of the major risk
factor for the progression of atherosclerosis and coronary artery disease. This study
focused on identifying the dysregulated molecular pathways and core genes that are
differentially regulated in FH and to identify the possible genetic factors and potential
underlying mechanisms that increase the risk to atherosclerosis in patients with FH.
Methods: The Affymetrix microarray dataset (GSE13985) from the GEO database and
the GEO2R statistical tool were used to identify the differentially expressed genes (DEGs)
from the white blood cells (WBCs) of five heterozygous FH patients and five healthy
controls. The interaction between the DEGs was identified by applying the STRING tool
and visualized using Cytoscape software. MCODE was used to determine the gene
cluster in the interactive networks. The identified DEGs were subjected to the DAVID
v6.8 webserver and ClueGo/CluePedia for functional annotation, such as gene ontology
(GO) and enriched molecular pathway analysis of DEGs.
Results: We investigated the top 250 significant DEGs (p-value < 0.05; fold two
change ≥ 1 or ≤ −1). The GO analysis of DEGs with significant differences revealed
that they are involved in critical biological processes and molecular pathways, such as
myeloid cell differentiation, peptidyl-lysine modification, signaling pathway of MyD88-
dependent Toll-like receptor, and cell-cell adhesion. The analysis of enriched KEGG
pathways revealed the association of the DEGs in ubiquitin-mediated proteolysis and
cardiac muscle contraction. The genes involved in the molecular pathways were shown
to be differentially regulated by either activating or inhibiting the genes that are essential
for the canonical signaling pathways. Our study identified seven core genes (UQCR11,
UBE2N, ADD1, TLN1, IRAK3, LY96, and MAP3K1) that are strongly linked to FH and
lead to a higher risk of atherosclerosis.
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Conclusion: We identified seven core genes that represent potential molecular
biomarkers for the diagnosis of atherosclerosis and might serve as a platform for
developing therapeutics against both FH and atherosclerosis. However, functional
studies are further needed to validate their role in the pathogenesis of FH
and atherosclerosis.
Keywords: familial hypercholesterolemia, atherosclerosis, coronary artery disease, functional enrichment
analysis, expression profiling data, gene expression arrays
INTRODUCTION
Atherosclerosis is a chronic immune-inflammatory disease that
is characterized by the progressive accumulation of lipids in
the intimal space of the atrial walls, which results in such
complications as chronic low-grade inflammation, endothelial
dysfunction, and oxidative stress. A high level of low-density
lipoprotein (LDL) in plasma induces atherosclerosis. In contrast,
a decreasing level of LDL cholesterol is associated with a
decreased frequency of severe cardiovascular events (Silverman
et al., 2016). Elevated levels of blood cholesterol are caused by a
group of genetic defects known as familial hypercholesterolemia
(FH). FH is one of the known genetic causes of premature
cardiovascular disease due to prolonged exposure to elevated
LDL, with a prevalence of ∼1:220 being observed (Abul-Husn
et al., 2016; Wald et al., 2016; Alhababi and Zayed, 2018).
Recent studies estimated the prevalence of heterozygous FH
(HeFH) to be significantly higher (1/220-250) than initially
reported (1/500) (Hopkins et al., 2011; Genest et al., 2014; Perez-
Calahorra et al., 2019). However, the homozygous FH (HoFH)
prevalence has been estimated to be 1 in 300,000–1,000,000
(Austin et al., 2004; Sjouke et al., 2015; de Ferranti et al., 2016;
Akioyamen et al., 2017; Alhababi and Zayed, 2018; Alonso et al.,
2018). The prevalence of FH is higher due to founder effect
that estimates to be upto 1 in 50–67 in some populations like
Lebanese, Ashkenazi Jews, French Canadians, Finns, Afrikaners,
and Tunisians (Leitersdorf et al., 1990; Nanchen et al., 2015;
Amor-Salamanca et al., 2017; Alonso et al., 2018). In the
past, the term FH was used to refer to defects in the LDL
receptor (Goldberg et al., 2011). Among FH patients, the clinical
phenotypes are distinctly versatile, even in patients who share
the same disease-causing mutation. This finding suggests that FH
is not a single disease but is a multifaceted syndrome (Hartgers
et al., 2015; Di Resta and Ferrari, 2018; Masana et al., 2019).
HeFH is mainly caused by mutations that occur in such genes as
LDLR, less frequently, mutations in APOB and PCSK9 genes can
be found in patients with phenotypic FH (Soutar and Naoumova,
2007; Gidding et al., 2015). Several studies reported that HoFH
causes considerable premature ASCVD, and would result in early
death if left untreated (males are at 50% risk, and females are
at 30% risk) (Slack, 1969; Stone et al., 1974; Joseph et al., 2001;
Naoumova et al., 2004; Vuorio et al., 2014). For the management
of patients above 75 years of age with clinically evident
Abbreviations: BP, biological process; FDR, false discovery rate; GO, gene
ontology; KEGG, kyoto encyclopedia of genes and genomes; MF, molecular
function.
atherosclerotic cardiovascular disease (ASCVD), the ACC/AHA
standards endorse a moderate intensity (but not a high-intensity)
statin (Vuorio et al., 2013, 2017; Stone et al., 2014). Microarray
technology is a robust procedure that is widely used to compare
genes that are differentially expressed in patients with different
diseases. This technology is also beneficial in understanding gene
association, mapping, expression, and linkage studies (Russo
et al., 2003). However, studies that investigated the white
blood cells (WBCs) transcriptome of patients with FH versus
healthy controls are limited. Therefore, this study aimed to
identify differentially expressed genes (DEGs), protein-protein
interactions, and dysregulated pathways that might be involved
in an increased risk of atherosclerosis due to FH.
MATERIALS AND METHODS
Array Data Acquisition and Processing
The GEO database from NCBI1 was used to access the GSE13985
dataset that contains expression profiles by array. The datasets
from various experiments are deposited in this database and
enable users to download the gene expression profiles stored
in GEO (Barrett et al., 2013). To seek GEO datasets for
related gene expression profiles, we used the keywords “Familial
Hypercholesterolemia” and “Microarray” and “Homo sapiens.”
GSE13985 contains ten samples, including five patients with
FH and five healthy control samples obtained with the help
of platform GPL570 [HG-U133_Plus_2] Affymetrix Human
Genome U133 Plus 2.0 Array (Režen et al., 2008). The five FH
patients and five controls were matched by age, BMI, sex, and
smoking status. The FH patients were free of clinical ASCVD.
The Blood samples were provided from the ten samples, and
RNA was extracted to be used for the array analysis. The gene
expression data were downloaded from the public database,
and in this study, there were no animal or human experiments
assisted by any of the authors.
Data Preprocessing and Identification of
DEGs
With the help of powerful multiarray technology, the preliminary
data from the dataset were made susceptible to the correction of
background, quantile normalization, and log transition (Irizarry
et al., 2003). Initial processing of the data involved altering
specific gene symbols from probe IDs with the help of a Entrez’s
Gene ID converter (Alibés et al., 2007). When the same gene
1https://www.ncbi.nlm.nih.gov/geo/
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contribution was observed in several samples, their mean value
was determined and considered as the eventual level of gene
expression. To examine the raw gene expression data, the online
statistical tool GEO2R was utilized, and the tool incorporated
the R/Bioconductor and Limma package v3.26.8 (Smyth, 2005;
Barrett et al., 2013; Ritchie et al., 2015). The GEO2R inbuilt
methods, such as T-test and Benjamini and Hochberg (false
discovery rate), were used to calculate the p-value and FDR
in order to determine the DEGs among patients with FH and
controls (Aubert et al., 2004). We set the principal standards of
| log (fold change) | > 1 and p < 0.05 to acquire DEGs that are
significant from the dataset, whereas the upregulated DEGs were
considered if the logFC ≥ 1 and logFC ≤ −1 for downregulated
DEGs. The RStudio (v1.2.5019) and library Calibrate package
were used to create the volcano plot. The subsequent DEGs were
attained from a dataset, and further investigation was performed
with selected DEGs. The heat map for the gene expression data
was generated using a heat mapper webserver.2 The inbuilt
average linkage clustering method was used to compute the
hierarchical clustering, and the Euclidean algorithm was used
for computing the distance between rows and columns (Babicki
et al., 2016). The flowchart diagram for this study is represented
in Figure 1.
Establishment of PPI Networks and
Module Analysis
We framed a PPI (protein-protein interaction) network by
utilizing the STRING web-based tool (v11.0, 3) to evaluate
the relationship among the DEGs from the attained datasets
(Szklarczyk et al., 2017, 2019). To eradicate the PPI interactions
that are in consistent from the dataset, we fixed the cutoff
standard to a confident interaction score ≥0.4. Therefore,
we attained a strong PPI network. Then, we combined the
outcomes from the STRING tool to Cytoscape software (v3.7.1,
4) to conceptualize the PPI interactions among the statistically
appropriate DEGs (Shannon et al., 2003). To recognize the
intersected clusters from the attained PPI network, we exploited
the Cytoscape plugin Molecular Complex Detection plugin
(MCODE). The group (cluster) determining extremities were
charted, such as Kappa score (K-core) fixed to five, Degree Cutoff
fixed to two, Max. Depth fixed to 100, and Node score Cutoff
fixed to 0.2, which constraints the cluster size for coexpressing
networks (Bader and Hogue, 2003). Further, we utilized the
GeneMANIA web server to perform the inter-relation analysis
and predict the function of the identified seven potential DEGs
(Warde-Farley et al., 2010; Franz et al., 2018).
DAVID and ClueGO Enrichment Analysis
For functional annotation of GO and analysis of KEGG pathway
enrichment, we used the web-based DAVID v6.8 tool.5 DAVID
is a significant source for any functional evaluation of the high-
throughput gene expression profiles (Huang et al., 2009a,b).
2http://heatmapper.ca/expression/
3http://www.string-db.org/
4http://www.cytoscape.org/
5https://david.ncifcrf.gov/
The results from DAVID was further imported to GOplot
in R Studio. The GOBubble and GOChord were used to
visualize the functional enrichment of the top 250 DEGs, which
facilitate the combination and integration of expression data with
functional assessment results (Walter et al., 2015). For integrative
analysis, we utilized both DAVID and ClueGO software to
comprehensively observe the DEGs involved in the GO terms
and pathways. The first DEGs from the GEO2R tool were
exposed to ClueGO v2.5.5/CluePedia v1.5.5 to attain complete
Gene Ontological terms (GO) and disease-related pathways
from the DEG dataset. ClueGO syndicates KEGG or BioCarta
pathways and GO, which delivers a fundamentally organized
pathway network or GO from the DEG dataset (Bindea et al.,
2009). Also, the study of molecular/biological function GO, and
enrichment of pathways analysis was conducted for DEGs, and
p-values < 0.05 were considered to be significant.
RESULTS
Data Acquisition and Identification of
DEGs
The GSE13985 dataset contained the gene expression profiles
of five patient samples with FH, and five control groups
(atherosclerotic markers in human blood - a study in patients
with familial hypercholesterolemia) were obtained from the GEO
database (Režen et al., 2008). The GPL570 platform (Affymetrix
Human Genome U133 Plus 2.0 Array) was used in this work.
Table 1 represents the original features of the patients and control
samples involved in this study. By using the publicly available
GEO2R tool, we identified the DEGs between FH patients and
healthy controls according to the cutoff values of | log2FC| ≥ 1.0
and p-values < 0.05, which were calculated based on the inbuilt
R/Bioconductor and limma package v3.26.8 from the GEO2R
tool, the top 250 DEGs were accordingly identified. The R studio
and library calibrate package was used to construct the volcano
plot to compare the DEGs between FH patients and healthy
controls. Figure 2 represents the volcano plot, and the significant
genes with satisfying values (p-value < 0.05, logFC ≥ 1, and
logFC ≤ −1) are labeled and shown in green dots. The top 250
DEGs identified between both groups were subjected to a heat
mapper web server to determine the expression level of the genes.
As a result, clustering based on hierarchy and heat maps was
generated and is depicted in Figure 3.
Establishment of PPI Networks and
Module Analysis
The physical and functional associations among the proteins
of DEGs of FH were assessed using the STRING tool. The
minimum required interaction score was set to the confidence
of 0.4. Simple tabular text output was generated from STRING.
The interaction among the query proteins was further visualized
using Cytoscape v3.7.1. Figure 4 represents the network with
96 nodes and 134 edges of PPI. The nodes denote the number
of proteins while edges and their interactions. The Cytoscape
plugin MCODE v1.5.1 interpreted the closely interlinked regions
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FIGURE 1 | Outline of the workflow and expression data analysis in the present study using bioinformatic strategies.
from the network of proteins in the form of clusters. The
top three clusters that are significant from the PPI network
with MCODE scores of 5, 5, and 4 were preferred. These
clusters are represented graphically in Figure 5. Cluster 1
was derived from node UQCR11 (Figure 5A). Cluster 2 and
Cluster 3 were derived from nodes TCEB1 and EZR, respectively
(Figures 5B,C). The tabular column represents the detailed
MCODE clusters of interlinked regions with their cluster
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TABLE 1 | Information on patients and controls primary features in GSE13985 from the GEO database.
Group Accession Title Organism Gender Age Disease State Tissue
Patient GSM351336 Patient 1 Homo sapiens Male 33 years Heterozygous familial hypercholesterolemia Blood
GSM351337 Patient 2 Homo sapiens Male 33 years Heterozygous familial hypercholesterolemia Blood
GSM351338 Patient 3 Homo sapiens Male 46 years Heterozygous familial hypercholesterolemia Blood
GSM351339 Patient 4 Homo sapiens Male 22 years Heterozygous familial hypercholesterolemia Blood
GSM351340 Patient 5 Homo sapiens Male 35 years Heterozygous familial hypercholesterolemia Blood
Control GSM351341 Control 1 Homo sapiens Male 35 years None Blood
GSM351342 Control 2 Homo sapiens Male 37 years None Blood
GSM351343 Control 3 Homo sapiens Male 22 years None Blood
GSM351344 Control 4 Homo sapiens Male 45 years None Blood
GSM351345 Control 5 Homo sapiens Male 33 years None Blood
FIGURE 2 | Visualization of DEGs volcano plots using R studio. The plot compared the DEGs between FH patients and controls from the dataset. The
representations are as follows: x-axis, logFC; y-axis, -log10 of a p-value. The p-values < 0.05 are in red dots, and logFC ≥ 1 and logFC ≤ –1 are in yellow dots; the
significant DEGs with both satisfying values are in green dots and indicated with gene names. Black dots indicate the remaining genes present in the array that were
not significantly changed. The genes that are upregulated in the array are on the right panel, and downregulated ones are on the left panel of the plot.
number, MCODE scores, node IDs, node numbers, and edge
numbers (Table 2).
DAVID Enrichment Analysis
For the functional annotation of DEGs, the DAVID v6.8 online
server was used. To ascertain the KEGG pathway-enriched
genes and the potential GO (Gene Ontology) classification,
terms approximating biological process, molecular functions,
and signaling pathways concerning KEGG pathways were used.
The modified Fisher exact p-value (EASE score) ≤ 0.05 and
FDR < 0.05 are considered strongly enriched. By analyzing
BP, we found that the DEGs from the complex PPI network
were enriched in myeloid cell differentiation (GO: 0030099),
intracellular transport (GO: 0046907), negative regulation of
response to DNA damage stimulus (GO: 2001021), peptidyl-
lysine modification (GO: 0018205), negative regulation of signal
transduction by p53 class mediator (GO: 1901797), and MyD88-
dependent toll-like receptor signaling pathway (GO: 0002755).
The Gene Ontology MF analysis revealed the involvement of
DEGs in antioxidant activity (GO: 0016209), p53 binding (GO:
0002039), thyroid hormone receptor binding (GO: 0046966),
cadherin binding involved in cell-cell adhesion (GO: 0098641),
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FIGURE 3 | Microarray heat map and clustering based on hierarchy for the
top 250 gene expression data from the datasets. n = 250 DEGs. Upregulated
genes are represented in red, and downregulated genes are represented in
green.
transcription factor activity, and transcription factor binding
(GO: 0000989). In addition, we utilized the DAVID online
method to classify the DEGs entailed in the different biological
pathways based on the KEGG reference database (p < 0.05;
FDR < 0.05). The KEGG pathway enrichment analysis revealed
the association of the DEGs in ubiquitin-mediated proteolysis
(hsa04120) and cardiac muscle contraction (hsa04260). The
annotated results for the following terms were tabulated
(Table 3). The GOBubble plots were constructed for the BP
and MF of the top 250 DEGs from the dataset (Figures 6A,B),
whereas the enriched cellular components of the identified DEGs
were plotted with GOChord (Figure 6C).
ClueGO/CluePedia Enrichment Analysis
The Cytoscape plugin ClueGO/CluePedia was used to study
the functional enrichment of the DEGs from the dataset.
ClueGo helped visualize the GO terms of the identified PPI
complex network. The MF and BF terms of the GO functional
enrichment analysis of the complex PPI network are depicted
in Figure 7. The statistical options for ClueGO enrichment
analysis were set based on a hypergeometric test that is two-
sided with p ≤ 0.05, Benjamini-Hochberg correction, and kappa
score ≥ 0.4 as a primary criterion. The BF and MF of DEGs
from the complex PPI network were predominantly enriched in
the negative regulation of intracellular transport (GO: 0032387),
endothelial cell development (GO: 0001885), scaffold protein
binding (GO: 0097110), regulation of DNA damage response
and signal transduction by p53 class mediator (GO: 0043516),
p53 binding (GO: 0002039), peptidyl-lysine trimethylation (GO:
0018023), antioxidant activity (GO: 0016209), positive regulation
of the Notch signaling pathway (GO: 0045747), and MyD88-
dependent Toll-like receptor signaling pathway (GO: 0002755)
(Figure 7). The KEGG and REACTOME pathway analysis from
ClueGO showed that many DEGs were significantly enriched
in cardiac muscle contraction (KEGG: 04260), regulation of
lipid metabolism by peroxisome proliferator-activated receptor
alpha (PPAR alpha) (R-HAS: 400206), transcriptional regulation
by RUNX3 (R-HAS: 8878159), ubiquitin-mediated proteolysis
(KEGG: 04120), renal cell carcinoma (KEGG: 05211), MyD88:
MAL (TIRAP) cascade initiated on plasma membrane (R-
HAS: 166058), and IRE1 alpha-activated chaperones (R-HAS:
381070) (Figure 8). Taken together, the results from ClueGO
enrichment clearly illustrate that the DEGs change the metabolic
behavior of the signaling pathways and are closely linked to
FH, contributing to the progression of such complications as
coronary artery disease and cardiovascular disease, which may
lead to atherosclerosis. Additionally, the dysregulated pathways
identified by our bioinformatics enrichment analysis could
play important roles in FH pathogenesis. However, functional
validations are needed to test our bioinformatics findings.
DISCUSSION
In the present study, we investigated the DEGs between five
patients with FH and five healthy controls with the GEO ID
of GSE13985 (Režen et al., 2008). We examined a total of
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FIGURE 4 | PPI networks show the interaction of DEGs from the GSE13985 dataset. The nodes and edges are retrieved from the STRING tool and plotted using
Cytoscape software. The nodes are displayed as Navajo white, while edges are shown as gray.
13,057 DEGs, and the top 250 significant DEGs were considered
for further studies (Supplementary Table S1). We found the
top three significant clusters that are distinguished by high
scores and closely interconnected regions from the networks
of PPI (Figures 5A–C). Screening the gene cluster could help
in determining the crucial genes and their interactions and
how they are associated with the pathogenesis and progression
of atherosclerosis. The clusters retrieved from MCODE were
often shown in the PPI network mechanisms, and representation
of clusters is crucial for a functional and comprehensive
understanding of network properties (Krogan et al., 2006;
Rahman et al., 2013). The densely interconnected nodes and
the less connected vertices of the PPI network were weighed
using the core clustering coefficient of the MCODE plugin. After
computation, an algorithm examined the weighted graph to
isolate the densely connected regions, which is considered as
clusters and represents the molecular complexes that formed with
DEGs (Sharan et al., 2007). From Table 2, we found three seed
nodes, namely, the UQCR11, TCEB1, and EZR genes that might
have been involved in the differential regulation of the pathway.
To explore the involvement of the 250 identified DEGs
in BP, MF, and molecular pathways of FH, we used the
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FIGURE 5 | Top three cluster subnetworks were identified from the PPI network with the help of Cytoscape using the MCODE plugin with a cluster score above
three. The aquamarine (ellipse) color indicates the nodes, while the edges are in gray. (A) Cluster 1; (B) Cluster 2; (C) Cluster 3.
built GO and KEGG enrichment to determine the functional
annotation of these genes. We found that these DEGs were
primarily enriched in myeloid cell differentiation, intracellular
transport, negative regulation of response to DNA damage
stimulus, peptidyl-lysine modification, negative regulation of
signal transduction by p53 class mediator, and the MyD88-
dependent Toll-like receptor signaling pathway. The analysis of
MF from GO showed that the DEGs were significantly enriched
in antioxidant activity, p53 binding, thyroid hormone receptor
binding, cadherin binding involved in cell-cell adhesion, and
transcription factor activity. Similarly, the analysis of KEGG
TABLE 2 | The most interlinked regions are clustered from the DEGs of
GSE13985 dataset using MCODE.
Cluster Score (Density x
No. of nodes)
Nodes Edges Node IDs
1 5 5 10 COX7A2, NDUFA6, UQCR11,
UQCRHL, COX6A1
2 5 5 10 FBXO30, HERC1, TCEB1,
UBE2N, RCHY1
3 4 4 6 EZR, SPTAN1, TLN1, MYH9
pathway enrichment showed that the DEGs are involved in
ubiquitin-mediated proteolysis and cardiac muscle contraction
(Table 3). Interestingly, MyD88-mediated signaling plays a
prominent role in the development of human atherosclerosis
and matrix degradation (Monaco et al., 2009). In line with this
finding, Yu et al. (2014) found that MyD88-deficient myeloid
cells are involved in the inhibition of macrophage recruitment
to adipose tissue and result in atherosclerosis and diet-induced
systemic inflammation (Yu et al., 2014). In this context, our
study identified the DEGs involved in the MyD88 signaling
pathway, such as IRAK3 (interleukin 1 receptor-associated kinase
3), LY96 (lymphocyte antigen 96), and MAP3K1 (mitogen-
activated protein kinase 1). Among these genes, LY96 and
MAP3K1 were significantly downregulated in the FH patients,
whereas IRAK3 was upregulated compared to the healthy
controls (Supplementary Figure S1). IRAK3 prevents IRAK1
and IRAK4 from dissociating from MyD88 and inhibits the
formation of IRAK-TRAF6 complexes (Lyu et al., 2018; Yu and
Feng, 2018). The increased expression of IRAK3, as shown in
Supplementary Figure S1A, typically coveys the dysregulation of
MyD88 and the TLR cascade via IRAK3 expression. Similarly, the
receptor complex resulting from the combination of LY96 and
Toll-like receptor 4 (TLR4) ectodomain mediates transduction
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TABLE 3 | Gene ontology (GO) terms such as biological process, molecular functions, and KEGG pathways of DEGs that are associated with familial
hypercholesterolemia from DAVID.
Category Term Count % p-value Fold enrichment FDR
GOTERM_BP_FAT GO:0030099∼Myeloid cell differentiation 10 4.9 4.9E-3 3.1 8.4E0
GOTERM_BP_FAT GO:0046907∼Intracellular transport 24 11.8 2.3E-2 1.6 3.4E1
GOTERM_BP_FAT GO:2001021∼Negative regulation of response to DNA damage stimulus 4 2.0 1.3E-2 8.1 2.1E1
GOTERM_BP_FAT GO:0018205∼Peptidyl-lysine modification 10 4.9 1.4E-2 2.6 2.2E1
GOTERM_BP_FAT GO:1901797∼Negative regulation of signal transduction by p53 class mediator 3 1.5 2.8E-2 11.4 4.0E1
GOTERM_BP_FAT GO:0002755∼MyD88-dependent toll-like receptor signaling pathway 3 1.5 3.8E-2 9.7 5.0E1
GOTERM_MF_FAT GO:0016209∼Antioxidant activity 4 2.0 3.9E-2 5.3 4.3E1
GOTERM_MF_FAT GO:0002039∼p53 binding 5 2.5 3.4E-3 8.0 4.8E0
GOTERM_MF_FAT GO:0046966∼Thyroid hormone receptor binding 3 1.5 2.6E-2 11.9 3.1E1
GOTERM_MF_FAT GO:0098641∼Cadherin binding involved in cell-cell adhesion 8 3.9 1.8E-2 3.0 2.3E1
GOTERM_MF_FAT GO:0000989∼Transcription factor activity, transcription factor binding 14 6.9 4.1E-3 2.5 5.7E0
KEGG_PATHWAY hsa04120:Ubiquitin mediated proteolysis 6 3.0 1.3E-2 4.2 1.4E1
KEGG_PATHWAY hsa04260:Cardiac muscle contraction 4 2.0 4.2E-2 5.1 3.9E1
FIGURE 6 | Bubble plot depicts the (A) biological process (BP-in orange), and (B) molecular function (MF-in green) of the GO terms from DAVID. The –log p-value
allocated to the y-axis and a Z-score to x-axis. The region of bubbles are significantly proportional to the number of DEGs in a given GO term. The threshold implies
the p-value standardized to 0.05 (orange line in BP and MF). (C) The association between the selected DEGs; their respective cellular component (CC) and GO
terms, along with the gene’s log2FC are presented in GOChord plot. The plot’s left half showed the DEGs that involved in different cellular components and the right
half displays the GO terms of cellular components in various colors. The colored bands connected a gene to a specific term GO.
of the lipopolysaccharide (LPS) signal across the cell membrane
(Gruber et al., 2004). A recent study found that LY96 can bind
to cholesterol (Choi et al., 2016), and TLR4 activation involves
agLDL, the predominant form of LDL found in atherosclerotic
plaques (Singh et al., 2020). Thus, our examined DEGs are reliable
with involvement in atherosclerosis-causing pathways.
To further refine the biological process, molecular
functions, and pathways defined from the analysis of
DAVID-GO terms (Figure 6), KEGG, and STRING, we
implemented the ClueGO plugin from Cytoscape, an
improved interpretation for biological terms, such as GO
and KEGG pathway analysis/BioCarta, and constructed a
functionally arranged network of terms GO/pathway. The
plugin also helps to visualize the networks that are functionally
grouped from more massive gene clusters (Bindea et al.,
2009). To acquire a detailed picture of the DEGs involved in
atherosclerosis, we utilized the ClueGO plugin to distinguish the
molecular pathways that are differentially regulated and their
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FIGURE 7 | Enrichment by Gene Ontology (GO) terms was visualized using the ClueGO/CluePedia plugin from Cytoscape. Vital molecular functions (MF) and
biological processes (BP) involved in the DEGs are shown with the specific gene interactions. The MF and BP enrichment analyses are inferred from the 250 top
DEGs PPI network. The connectivity of the GO terms network described by functional nodes and edges that are shared between the DEGs with a kappa score of
0.4. The enrichment shows only significant GO terms (p-value ≤ 0.05). The values of p ≤ 0.05 indicate the node size. The node color code indicates the specific
functional class that they are involved in. The color represents various molecular function and biological process involved in the enrichment analysis. The bold fonts
indicate the most important functional GO terms that define the names of MF and BP of each group. The names of the DEGs involved in each group are displayed in
red font.
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FIGURE 8 | Enrichment by pathway terms is visualized using the ClueGo/CluePedia plugin from Cytoscape. The plugin delivers a comprehensive enrichment
analysis for DEGs, including KEGG and REACTOME pathways. The connectivity of the pathways in the network described by functional nodes and edges that are
shared between the DEGs with a kappa score of 0.4. The enrichment shows only significant pathways (p-value ≤ 0.05). The values of p ≤ 0.05 indicate the node
size. The node color code indicates the specific functional class that they are involved in. The color represents various molecular pathways involved in the enrichment
analysis of the identified DEGs. The bold fonts indicate the most critical functional pathways that define the names of the signaling pathway of each group. The
names of the DEGs involved in each group are displayed in red font.
significant gene interactions depending on the p-values and
kappa statistics.
Among the enriched biological process and molecular
pathways, we identified that ubiquitin-mediated proteolysis,
cardiac muscle contraction, MyD88-dependent Toll-like receptor
signaling pathway, and IRE1 alpha-activated chaperones were
considered dysregulated and are significant to atherosclerosis
progression in FH patients based on kappa statistics and p-values
(Figures 7, 8). Additionally, we also identified the genes that are
significant in the dysregulated molecular pathways and involved
in FH progression. In line with this finding, UQCR11, UBE2N,
ADD1, TLN1, IRAK3, LY96, and MAP3K1 were found to be
associated with the risk of Atherosclerosis in FH patients.
This study identified DEGs that are involved in ubiquitin-
mediated proteolysis, IRE1 alpha-activated chaperones, and
cardiac muscle contraction, such as UQCR11, UBE2N, TLN1,
and ADD1, respectively. As shown in Supplementary Figure S2,
a significant gene expression level was shown between the
FH patients and healthy control samples. In this study, the
expression levels of the UQCR11 and UBE2N genes were
significantly reduced, and the expression levels of the TLN1
and ADD1 genes were notably increased in the FH patients
compared with the healthy controls. Our identified novel
DEGs from the dataset indeed have high consistency with the
risk of atherosclerosis and are involved in the dysregulation
of such pathways as ubiquitin-mediated proteolysis, IRE1
alpha-activated chaperones, and cardiac muscle contraction.
For instance, the transfer of ubiquitin from UBE2N to LDLR
is required for its lysosomal degradation. The reduced gene
expression level of UBE2N leads to skipping this event and
might result in the accumulation of LDLR in the lysosome
(Zhang et al., 2012).
Additionally, the polymorphism (p.G460W) present in ADD1
has reportedly contributed to the increased risk factor for
coronary heart disease (Morrison et al., 2002). Our study
clearly showed the increased expression of ADD1 from the
FH patient dataset, which could alter the casual signaling of
IRE1 alpha-activated chaperones (Supplementary Figure S2D).
TLN1 functions as a molecular scaffolding protein and can
contribute to the signaling of adhesion through its binding
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FIGURE 9 | Analysis of the interrelation between the identified core genes. GeneMANIA was used to map the network, and Cytoscape was used for network
visualization. The genes LY96, IRAK3, MAP3K1, and UBE2N are involved in the Toll-like receptor cascade and MyD88:MAL (TIRAP) cascade; ADD1 and TLN1 are
involved in ubiquitin-mediated proteolysis, IRE1alpha activates chaperones, and UQCR11 is involved in cardiac muscle contraction.
partners, translating mechanical signals into chemical signals
(Hytönen and Wehrle-Haller, 2014). The TLN1 expression
level in atherosclerotic plaques is significantly reduced, and
it plays a central role in cell adhesion, indicating that tissue
disintegration in atherosclerosis may be partly induced by TLN1
downregulation, leading to cell-ECM interaction loosening and
tissue reorganization (Essen et al., 2016). However, our dataset
showed increased expression of TLN1, which might differentially
regulate and activate IRE1alpha chaperones. Yet, recent research
has identified that proatherogenic gene expression is regulated by
IRE1, which includes several essential chemokines and cytokines
(Tufanli et al., 2017).
To establish the interrelationship between the core genes
UQCR11, UBE2N, ADD1, TLN1, IRAK3, LY96, and MAP3K1,
this interrelationship will help in understanding the coexpression
and molecular pathways that pertain to FH. It is essential
to comprehend the interactions between the core genes since
these genes dysregulate the general molecular pathways in FH
patients (Kumar et al., 2019; Udhaya Kumar et al., 2020).
The differentially expressed genes might be responsible for
the clinical phenotypes of the patients and the progression
of atherosclerosis. We found that the Toll-like receptor and
MyD88:MAL (TIRAP) cascades are activated by such DEGs
as LY96, IRAK3, MAP3K1, and UBE2N (Monaco et al., 2009;
Yu et al., 2014). Similarly, UQCR11 is directly involved in
cardiac muscle contraction and has a physical interaction
between LY96, TLN1, and UBE2N. The TLN1 and ADD1 genes
directly associated with IRE1alpha-activated chaperones and
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ubiquitin-mediated proteolysis (Figure 9). Taken together, our
observed findings suggest that the involvement of core genes
related to the risk of atherosclerosis might be a critical metric in
ubiquitin-mediated proteolysis, Toll-like receptor, and MyD88:
MAL (TIRAP) cascades and a beneficial tool for diagnosis and
targeted therapy. In addition, the FH patients were free of
clinical ASCVD, and the patient 2 and 5 did not receive lipid-
lowering treatment, whereas the patient 1, 3, and 4 received
lovastatin, simvastatin, and atorvastatin, respectively. This drug
is also given to the patients as primary and secondary prevention
that develops the risk of ASCVD and for those who already
developed ASCVD, respectively (Taylor et al., 2013; Vuorio
et al., 2013). With the help of a clinical diagnostic strategy,
approximately 50% of patients are identified in FH, which is
a cost-effective process. Indeed, a diagnosis by screening the
cascades is a systematic and useful tool for diagnosing FH patients
before the development of Atherosclerosis (Marks et al., 2002;
Leren et al., 2008).
In general, FH can be progressed through many cellular and
molecular mechanisms, and pathways. A recent study claimed
that the COX7B is a potential novel gene target for FH treatment
(Li et al., 2015); however, authors did not provide supportive
evidence for metabolic network and pathway links between the
Atherosclerosis and FH. Later, a similar study claimed that
the RPL17 and ribosome protein-related genes might increase
the atherosclerotic risk. Although the study mentioned that
these genes are downregulated in the FH patient’s blood cells,
they are significantly upregulated in the reported dataset. In
addition, they claimed that cytochrome-c oxidase genes could
contribute to atherosclerosis development, yet there was no
substantial evidence provided (Wang and Zhao, 2016). The
study conducted by Smolock et al. (2012) suggested that RPL17
acts as an inhibitor for vascular smooth muscle cells (VSMC)
and might be a therapeutic target to limit the thickening
of carotid intima (Smolock et al., 2012). However, increased
expression of RPL17 showed to inhibit the VSMC, reducing the
progression of atherosclerosis, which could be a regular event that
occurs in FH patients.
Interestingly, our functional enrichment analysis did
not capture any biological/molecular functions related to
inflammatory responses, as some patients with FH had shown
inflammatory responses due to increased expression level of the
molecules associated with tumor necrosis factor (TNF) (Fadini
et al., 2014; Holven et al., 2014; Escate et al., 2018). The possible
reason for this might be that the patients with FH in our study
do not have any phenotypes characteristics to inflammation;
consistent with the nature of FH, as it is a frequent disease (1/220-
250) with a high variation in phenotypic expression associated
with ASCVD (Alhababi and Zayed, 2018; Perez-Calahorra et al.,
2019). Also, in era of personalized medicine, it is significant
to identify the possible targeted therapy using advanced omics
technologies (Prodan Žitnik et al., 2018).
Our study is the first to identify the association of core
DEGs to the dysregulated pathways in FH patients. Our
study recommends to screen WBCs from patients with FH
to determine the metabolic and genetic factors that may
help in identifying potential cardiovascular risks and might
provide better diagnosis and improved therapy for the disease.
The limitation of the present research is the small patient
groups; therefore, investigating a larger sample size in different
populations would help to confirm our data. The limitations of
this study include; first, FH patients were free of clinical ASCVD
and not possible to know if they have subclinical atherosclerosis
by imaging. Second, the number is too small; therefore, it is
important to study a larger cohort of patients that have clinical
ASCVD that are compared with ones with no clinical ASCVD.
Finally, no data were available for the LDL-C or TC of the FH
patients in the GSE13985 dataset.
CONCLUSION
Most FH patients do not exhibit atherosclerotic symptoms
in clinical diagnostic procedures. The findings using a
transcriptome analysis from WBCs of FH patients and healthy
controls to identify atherosclerotic markers are highly limited.
Overall, our systematic interpretation demonstrated an essential
role of DEGs and their essential role in the occurrence,
development of FH, and increased risk of atherosclerosis.
Our study identified a total of 250 genes that are differentially
expressed and seven essential genes that are associated with FH
patients compared to healthy controls. The study of expression
from WBCs and the association with DEGs may help to elucidate
the role played by these DEGs in FH progression and the
development of atherosclerosis. Finally, we identified seven novel
potential target genes (UQCR11, UBE2N, ADD1, TLN1, IRAK3,
LY96, and MAP3K1), which might be valid targets for therapeutic
development for FH, and might be used as diagnostic biomarkers
for FH patients and prognostic indicators for atherosclerosis
using WBCs from FH patients; however, functional studies are
needed to validate their proposed role in FH and atherosclerosis.
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